BR0010338A - Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound - Google Patents

Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound

Info

Publication number
BR0010338A
BR0010338A BR0010338-1A BR0010338A BR0010338A BR 0010338 A BR0010338 A BR 0010338A BR 0010338 A BR0010338 A BR 0010338A BR 0010338 A BR0010338 A BR 0010338A
Authority
BR
Brazil
Prior art keywords
compound
cck
preparation
disease
treating
Prior art date
Application number
BR0010338-1A
Other languages
Portuguese (pt)
Inventor
David Colclough
Anne Hodgson
Jerzy Ryszard Szewczyk
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910366.5A external-priority patent/GB9910366D0/en
Priority claimed from GBGB0008179.4A external-priority patent/GB0008179D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0010338A publication Critical patent/BR0010338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO ENANCIOMERICAMENTE ENRIQUECIDO, COMPOSIçãO FARMACêUTICA, MéTODO PARA TRATAR UMA DOENçA OU CONDIçãO MEDIADA POR CCK-A, USO DE UM COMPOSTO, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Um composto enanciomericamente enriquecido de Fórmula (I) é exposto, processos para a sua preparação, composições farmacêuticas que o contêm e o uso dos mesmos, para o tratamento de doenças ou condições mediadas por CCK-A, tais como obesidade."ENANCIOMERICALLY ENRICHED COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE OR CONDITION MEDIATED BY CCK-A, USE OF A COMPOUND, AND, PROCESS FOR THE PREPARATION OF A COMPOUND". An enanciomerically enriched compound of Formula (I) is exposed, processes for its preparation, pharmaceutical compositions containing it and the use of them, for the treatment of diseases or conditions mediated by CCK-A, such as obesity.

BR0010338-1A 1999-05-06 2000-05-04 Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound BR0010338A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9910366.5A GB9910366D0 (en) 1999-05-06 1999-05-06 1,5-Benzodiazepine Derivatives
GBGB0008179.4A GB0008179D0 (en) 2000-04-05 2000-04-05 Chemical process
PCT/EP2000/003982 WO2000068209A2 (en) 1999-05-06 2000-05-04 1,5-benzodiazepine derivatives as cck-a receptor agonists

Publications (1)

Publication Number Publication Date
BR0010338A true BR0010338A (en) 2002-02-13

Family

ID=26244033

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010338-1A BR0010338A (en) 1999-05-06 2000-05-04 Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound

Country Status (21)

Country Link
EP (1) EP1212305A2 (en)
JP (1) JP2002544200A (en)
KR (1) KR20020012567A (en)
CN (1) CN1161345C (en)
AR (1) AR022044A1 (en)
AU (1) AU4754800A (en)
BR (1) BR0010338A (en)
CA (1) CA2370801A1 (en)
CO (1) CO5170461A1 (en)
CZ (1) CZ20013988A3 (en)
HK (1) HK1046138A1 (en)
HU (1) HUP0201181A3 (en)
IL (1) IL146124A0 (en)
MX (1) MXPA01011267A (en)
MY (1) MY138319A (en)
NO (1) NO20015397L (en)
NZ (1) NZ515048A (en)
PE (1) PE20010110A1 (en)
PL (1) PL351546A1 (en)
TR (1) TR200103169T2 (en)
WO (1) WO2000068209A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035793A2 (en) * 2003-10-09 2005-04-21 Decode Genetics Ehf. Cckar markers and haplotypes associated with extreme weight conditions
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
BR112022006546A2 (en) 2019-10-07 2022-08-30 Kallyope Inc GPR119 AGONISTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin

Also Published As

Publication number Publication date
JP2002544200A (en) 2002-12-24
MXPA01011267A (en) 2002-05-06
MY138319A (en) 2009-05-29
WO2000068209A3 (en) 2001-03-01
WO2000068209A2 (en) 2000-11-16
EP1212305A2 (en) 2002-06-12
KR20020012567A (en) 2002-02-16
TR200103169T2 (en) 2002-04-22
HK1046138A1 (en) 2002-12-27
CA2370801A1 (en) 2000-11-16
HUP0201181A3 (en) 2003-10-28
NZ515048A (en) 2004-01-30
CZ20013988A3 (en) 2002-02-13
AR022044A1 (en) 2002-09-04
PE20010110A1 (en) 2001-03-05
CO5170461A1 (en) 2002-06-27
IL146124A0 (en) 2002-07-25
AU4754800A (en) 2000-11-21
CN1161345C (en) 2004-08-11
CN1362949A (en) 2002-08-07
PL351546A1 (en) 2003-05-05
NO20015397D0 (en) 2001-11-05
HUP0201181A2 (en) 2002-12-28
NO20015397L (en) 2001-11-05

Similar Documents

Publication Publication Date Title
BR9509683A (en) Compounds and processes for treating a clinical condition in a mammal for treating a hyperlipidemic condition in a manifer and for preparing a compound
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
BR0313266A (en) Compounds, their preparation and use processes, pharmaceutical formulation and methods for preventing and / or treating a mglur5 receptor mediated disorder and inhibiting mglur5 receptor activation
BR9911488A (en) Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
AR014261A1 (en) BENZOTIAZEPINE HYPOLIPIDEMIC COMPOUNDS, COMPOSITIONS AND PROCESS FOR PREPARATION
BR0108600A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and methods for treating a chemokine-mediated disease and for treating an inflammatory disease
BR9502707A (en) Compound pharmaceutical composition and method for treating a condition
BRPI9710372B8 (en) compound, and, pharmaceutical composition.
BR0010555A (en) Neuraminidase Inhibitors
BR9808953A (en) Compound, process to treat a cyclooxygenase-2 mediated disorder in a patient, and pharmaceutical composition
UY26130A1 (en) COMPOUNDS TO TREAT OBESITY
BR9713465A (en) Cytically substituted amine metallotprotease inhibitors
BRPI0411255A (en) compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound
BR0209127A (en) compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BR0209129A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds.
BRPI0417376A (en) compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use
BR0206514A (en) Compound, method of treating a human or animal suffering from migraine, use of the compound, pharmaceutical composition, and process for preparing a compound
KR950031060A (en) Pharmaceutical composition for the treatment of osteoporosis
BRPI0114344B8 (en) retinoid compound, its use, its pharmaceutical composition and its preparation process
DE69413829D1 (en) ANTIGLUCOCORTICOIDSTEROIDS FOR TREATING ANXIETY DISORDERS
BR0209128A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BR9809234A (en) Compound, pharmaceutical composition, use of a compound, processes to treat or prevent diseases of the endocrinological system, to manufacture a drug, to prepare a compound and a set, and use of it.
DE69918972D1 (en) USE OF NMDA ANTAGONISTS AND / OR SODIUM CHANNEL ANTAGONISTS FOR TREATING INFLAMMABLE DISEASES
BR9909870A (en) Pyrrolidines as inhibitors of neuraminidases
BR0010338A (en) Enanciomerically enriched compound, pharmaceutical composition, method for treating a disease or condition mediated by cck-a, use of a compound, and process for the preparation of a compound

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.